Cargando…

(177)Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial

PURPOSE: Lutetium-177 prostate-specific membrane antigen-617 ((177)Lu-PSMA-617) in end-stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable outcomes. In this study, we aimed to prospectively compare the efficacy and safety of (177)Lu-PSMA-617 and docetaxel in chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satapathy, Swayamjeet, Mittal, Bhagwant Rai, Sood, Ashwani, Das, Chandan Krushna, Mavuduru, Ravimohan Suryanarayan, Goyal, Shikha, Shukla, Jaya, Singh, Shrawan Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627907/ https://www.ncbi.nlm.nih.gov/pubmed/34842950 http://dx.doi.org/10.1007/s00259-021-05618-3

Ejemplares similares

Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer
por: Satapathy, Swayamjeet, et al.
Publicado: (2020)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Extended therapy with [(177)Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

(177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience
por: Satapathy, Swayamjeet, et al.
Publicado: (2021)

Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy
por: Rosar, Florian, et al.
Publicado: (2021)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

PSMA-617 inhibits proliferation and potentiates the (177)Lu-PSMA-617-induced death of human prostate cancer cells
por: Zhao, Yi, et al.
Publicado: (2023)

[(177)Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
por: Tönnesmann, Roswitha, et al.
Publicado: (2019)

Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Characterization of Non-Specific Uptake and Retention Mechanisms of [(177)Lu]Lu-PSMA-617 in the Salivary Glands
por: Heynickx, Nathalie, et al.
Publicado: (2023)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Hematological Toxicity in Mice after High Activity Injections of (177)Lu-PSMA-617
por: Kristiansson, Amanda, et al.
Publicado: (2022)

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2020)

Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
por: Rosar, Florian, et al.
Publicado: (2021)

[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2022)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Outcome of (177)Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2021)

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review
por: Heidegger, Isabel, et al.
Publicado: (2022)

Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
por: Rosar, Florian, et al.
Publicado: (2021)

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radioligand Therapy
por: Gaal, Sebastian, et al.
Publicado: (2023)

First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
por: Klein Nulent, Thomas J. W., et al.
Publicado: (2021)

Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy
por: Brosch-Lenz, Julia, et al.
Publicado: (2023)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Preliminary experience with dosimetry, response and patient reported outcome after (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
por: Fendler, Wolfgang P., et al.
Publicado: (2016)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

Salvage Radioligand Therapy with Repeated Cycles of (177)Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
por: Groener, Daniel, et al.
Publicado: (2021)

Long-term outcome of (177)Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Single Center Experience with a 4-Week (177)Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Kemppainen, Jukka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tg8hdrmgjdm4dt9u697nlpbtsd